Corrections Made to Abstract of Stage IV Breast Cancer Study

Overview

The original investigation on stage IV breast cancer incidence and survival was corrected to address errors in the Abstract Results. The correction specifically pertains to inaccuracies in the reported increases of stage IV diagnoses across various breast cancer subtypes.

Background

Accurate reporting of cancer incidence and survival data is crucial for understanding trends. This correction reflects ongoing efforts to ensure the integrity of published medical literature.

Data Highlights

No numerical data is provided in the source material.

Key Findings

• The original article titled 'Stage IV Breast Cancer Incidence and Survival, 2010-2021' was published on May 12, 2026.
• Errors in the Abstract Results regarding stage IV diagnoses were corrected online on July 15, 2026.
• The corrected data pertains to increases in percentage of stage IV diagnoses in various breast cancer subtypes.
• Accurate epidemiological data is essential for guiding treatment and research in metastatic breast cancer.
• The correction emphasizes the importance of peer review and accuracy in clinical publications.

Clinical Implications

Healthcare professionals should remain aware of the corrections made to published studies, as they can impact clinical understanding and treatment approaches. Continuous monitoring of literature for updates is essential for informed clinical practice.

Conclusion

The correction of the abstract in the stage IV breast cancer study underscores the necessity for accuracy in clinical research reporting. Such corrections are vital for maintaining the reliability of medical literature.

Related Resources & Content

1. Agresti R, Sandri M, Capri G, et al., JAMA Network Open, 2026 -- Stage IV Breast Cancer Incidence and Survival, 2010-2021
2. BJS (British Journal of Surgery) — Erratum: Comparison of Axillary Surgery and Non-Axillary Staging in T1N0 Breast Cancer: Two-Decade Follow-Up of the INT 09/98 Randomized Clinical Trial
3. Journal of Neuro-Oncology — Erratum: A Prospective Investigation of Keyhole Craniotomy and Stereotactic Brachytherapy for Newly Diagnosed Brain Oligometastases
4. The ASCO Post — Erratum
5. Surgical Endoscopy — Amendment to: Surgical and Oncological Results of Laparoscopic Right Hemicolectomy (D3 + CME) for Colorectal Cancer: A Prospective Cohort Study from a Single Center
6. Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
7. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line treatment
8. Stage IV Breast Cancer Incidence and Survival, 2010-2021 | Oncology | JAMA Network Open | JAMA Network
9. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer | FDA
10. Comparative efficacy and safety of sacituzumab govitecan versus chemotherapy in metastatic breast cancer: An updated meta-analysis and systematic review. | Journal of Clinical Oncology